Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
Fintel on MSN

UBS upgrades BioNTech SE - Depositary Receipt (BNTX)

Fintel reports that on May 27, 2026, UBS upgraded their outlook for BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) from ...

Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions

The confirmed overall response rate (cORR) for patients with squamous non-small cell lung cancer hit 68.4% when pumitamig was combined with chemotherapy — but the most striking figure came from a ...

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...
Fierce Biotech

In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

German vaccine maker BioNTech to cut up to 1,860 jobs, close plants

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, plans to close several production sites, with up to 1,860 jobs affected. The ...

With 1,860 Job Cuts and a $1 Billion Buyback, BioNTech's ASCO Data Will Define Its Next Chapter

The show of hands at this year's ASCO annual meeting is unmistakable. BioNTech is presenting more than 25 clinical studies in Chicago, including 13 pivotal trials — an extraordinary concentration of ...

BioNTech Highlights Late-Stage Oncology Pipeline and New Data Ahead of 2026 ASCO Meeting

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds An update from ...
STAT

With promising early data in triple negative breast cancer, a new bispecific heats up

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...
STAT

BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BioNTech said Thursday it would buy ...

BioNTech Expands Supervisory Board To Support Oncology Pipeline And Commercial Plans

BioNTech’s 2026 AGM approved an expansion of the Supervisory Board. Two new members with backgrounds in oncology, commercialization, and clinical development were appointed. The board change aligns ...
MedCity News

BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...